Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Health-Related QoL Poor Among Myeloma, Pancreatic Cancer Survivors

November 11, 2014
By Leah Lawrence
Article

Survivors of multiple myeloma and pancreatic cancer may have some of the poorest physical health-related quality of life outcomes, according to a new study.

Although researched less, survivors of cancers that occurred at less common sites may also have poor health-related quality of life (HRQOL) outcomes, particularly among survivors of multiple myeloma and pancreatic cancer.

Erin E. Kent, PhD, of the National Cancer Institute, and colleagues used data from the Surveillance, Epidemiology, and End Results (SEER) national cancer registry system and the Medicare Health Outcomes Survey (MHOS) to research HRQOL in more than 16,000 cancer survivors.

“Most studies of HRQOL among cancer patients and survivors have been limited to breast cancer and, to a lesser extent, prostate, colorectal, and lung cancer, and even fewer studies have examined HRQOL among older long-term survivors,” Kent and colleagues wrote in Cancer. “However, much less is known about the HRQOL experiences of individuals with one of the less common malignancies.”

Therefore, in this study, the researchers looked at patients with kidney cancer, bladder cancer, pancreatic cancer, upper gastrointestinal cancer, cancer of the oral cavity and pharynx, uterine cancer, cervical cancer, thyroid cancer, melanoma, chronic leukemia, non-Hodgkin lymphoma, and multiple myeloma. Outcomes of the 36-Item Short Form Health Survey and the Veterans RAND 12-Item Health Survey were examined and compared to individuals without cancer.

Overall, cancer survivors had lower average Physical Component Scores (PCS) than did individuals without cancer. However, Mental Component Scores (MCS) did not greatly differ between the two groups. A utility metric (Short Form 6D/Veterans RAND 6D), which adjusted for chronic conditions and sociodemographic characteristics, was also calculated.

The lowest PCS and MCS scores reported were among survivors of multiple myeloma (31.3 and 48.8) and pancreatic cancer (35.3 and 48). Survivors of multiple myeloma also had the lowest mean Short Form 6D/Veterans RAND 6D score of 0.63, which was 0.10 points different from individuals without cancer.

Bodily pain, Role-Physical, and Vitality were all prominent concerns among survivors of pancreatic cancer and myeloma, with these two cancer type survivors reporting the lowest mean scores for Role-Physical.

“The disease burden, as evidenced by the current study and a few other published reports of multiple myeloma and pancreatic cancer, suggests the need for research to identify factors that contribute to inferior outcomes among respondents with these malignancies,” the researchers wrote.

In addition, the researchers noted that further research was needed in patients with even less common cancers, such as liver cancer, who were not well-represented in the SEER-MHOS databases.

Recent Videos
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Skin toxicities are common with targeted therapies for GI malignancies but can be remedied by preventative measures and a collaboration with dermatology.
Combining daratumumab with other agents is one strategy that investigators are exploring in the smoldering multiple myeloma field.
A substantial portion of patients who received daratumumab in the AQUILA study were able to delay disease progression to active multiple myeloma.
The approval of daratumumab validates the notion of using limited therapy to help delay progression from smoldering disease to multiple myeloma.
Related Content
Advertisement

The Intricacies of Bispecific Antibodies in Multiple Myeloma

The Intricacies of Bispecific Antibodies in Multiple Myeloma

ONCOLOGY Staff
December 7th 2025
Article

Experts at the 2025 IMS Annual Meeting discussed bispecific antibodies as treatment for multiple myeloma, highlighting various treatment strategies and real-world data insights.


Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD
December 1st 2025
Podcast

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.


Early Response Rates Noted With Elranatamab/Iberdomide in R/R Multiple Myeloma

Early Response Rates Noted With Elranatamab/Iberdomide in R/R Multiple Myeloma

Kristi Rosa
December 6th 2025
Article

Results from the MagnetisMM-30 trial showed early ORR data with elranatamab/iberdomide in R/R multiple myeloma.


Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap

Nicholas James Hornstein, MD, PhD;Timothy Brown, MD;Udhayvir S. Grewal, MD
November 3rd 2025
Podcast

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.


Outcomes were comparable in the transplant-ineligible population, with KRd and VRd producing identical progression or death rates of 30%.

KRd Exhibits PFS Advantage vs VRd in Newly Diagnosed Multiple Myeloma

Jax DiEugenio
December 6th 2025
Article

Outcomes were comparable in the transplant-ineligible population, with KRd and VRd producing identical progression or death rates of 30%.


The 2.5 year progression-free survival rate was 80.5% with cilta-cel for this population, suggesting a potential cure fraction.

Cilta-Cel Exhibits Long-Term Survival in Standard-Risk R/R Multiple Myeloma

Chris Ryan
December 6th 2025
Article

The 2.5 year progression-free survival rate was 80.5% with cilta-cel for this population, suggesting a potential cure fraction.

Related Content
Advertisement

The Intricacies of Bispecific Antibodies in Multiple Myeloma

The Intricacies of Bispecific Antibodies in Multiple Myeloma

ONCOLOGY Staff
December 7th 2025
Article

Experts at the 2025 IMS Annual Meeting discussed bispecific antibodies as treatment for multiple myeloma, highlighting various treatment strategies and real-world data insights.


Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD
December 1st 2025
Podcast

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.


Early Response Rates Noted With Elranatamab/Iberdomide in R/R Multiple Myeloma

Early Response Rates Noted With Elranatamab/Iberdomide in R/R Multiple Myeloma

Kristi Rosa
December 6th 2025
Article

Results from the MagnetisMM-30 trial showed early ORR data with elranatamab/iberdomide in R/R multiple myeloma.


Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap

Nicholas James Hornstein, MD, PhD;Timothy Brown, MD;Udhayvir S. Grewal, MD
November 3rd 2025
Podcast

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.


Outcomes were comparable in the transplant-ineligible population, with KRd and VRd producing identical progression or death rates of 30%.

KRd Exhibits PFS Advantage vs VRd in Newly Diagnosed Multiple Myeloma

Jax DiEugenio
December 6th 2025
Article

Outcomes were comparable in the transplant-ineligible population, with KRd and VRd producing identical progression or death rates of 30%.


The 2.5 year progression-free survival rate was 80.5% with cilta-cel for this population, suggesting a potential cure fraction.

Cilta-Cel Exhibits Long-Term Survival in Standard-Risk R/R Multiple Myeloma

Chris Ryan
December 6th 2025
Article

The 2.5 year progression-free survival rate was 80.5% with cilta-cel for this population, suggesting a potential cure fraction.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.